Newsletter Tool

To view this email as a web page, click here

Today's Rundown

Moderna has sewn up $18 billion in COVID-19 vaccine orders—and it's negotiating more
Hospital groups make new press to Senate to add more money to provider relief fund
GSK fails COVID-19 phase 2, subgroup finding fuels further work
Three-shot combo? Pfizer, BioNTech roll COVID-19 booster trial as real world data back first vaccine
Hospitals could lose between $53B and $122B this year due to pandemic
Insights into how coronavirus changes shape could aid development of COVID-19 vaccines, drugs
UPDATED Coronavirus tracker: HPV vaccinations down amid pandemic, BCBSA data show
COVID-19 tracker: Altimmune to test nasal vaccine; Moderna racking up huge sales
Foresite banks $969M to back companies tackling healthcare challenges highlighted by pandemic
Moderna's CMO Zaks quits for 'next leg of his career' after swift move to commercial focus

Featured Story

Moderna has sewn up $18 billion in COVID-19 vaccine orders—and it's negotiating more

By Eric Sagonowsky

Moderna, racing to produce as many COVID-19 vaccine doses as possible this year, says it expects to reap $18.4 billion from its shot this year.

Hospital groups make new press to Senate to add more money to provider relief fund

By Robert King

Hospital groups wrote a letter to Senate leadership Thursday pressing for more money to be included in a provider relief fund, saying that most of the $178 billion in the fund has been allocated.

GSK fails COVID-19 phase 2, subgroup finding fuels further work

By Nick Paul Taylor

A phase 2 clinical trial of GlaxoSmithKline’s otilimab in hospitalized COVID-19 patients has missed its primary endpoint. However, a preplanned analysis of older patients found signs of efficacy, leading GSK to expand the cohort in a bid to validate the finding.

Three-shot combo? Pfizer, BioNTech roll COVID-19 booster trial as real world data back first vaccine

By Beth Snyder Bulik

Pfizer and BioNTech are rolling out a study to test a third dose of its Comirnaty COVID-19 vaccine against coronavirus variants while talking with regulators about trialing a booster specifically designed to tackle them. The news comes as a real-world study confirms just how effective its two-dose regimen has been so far.

Hospitals could lose between $53B and $122B this year due to pandemic

By Robert King

Hospitals could lose between $53 billion and $122 billion in 2021 due to the lingering impact of the pandemic as providers seek to add $35 billion to a provider relief fund.

Insights into how coronavirus changes shape could aid development of COVID-19 vaccines, drugs

By Angus Liu

Scientists continue to search for vaccines and drugs to add to the anti-COVID-19 arsenal. Now two research groups have announced discoveries related to the changing structure of the SARS-CoV-2 coronavirus that caused the pandemic, and they believe their insights could aid in the development of new weapons to fight the virus.

UPDATED Coronavirus tracker: HPV vaccinations down amid pandemic, BCBSA data show

By Healthcare Staff

Follow along with the latest COVID-19 news straight from the Fierce Healthcare team.

COVID-19 tracker: Altimmune to test nasal vaccine; Moderna racking up huge sales

By Kevin Dunleavy,Fraiser Kansteiner,Eric Sagonowsky,Angus Liu,Conor Hale

Altimmune will begin testing a single-dose, needle-free nasal COVID-19 vaccine. Moderna has made advance purchase vaccine agreements totaling $18.4 for 2021. AstraZeneca will use 'global capacity' to fulfill vaccine pacts. A National Geographic film will chronicle how Pfizer-BioNTech developed their COVID-19 vaccine.

Foresite banks $969M to back companies tackling healthcare challenges highlighted by pandemic

By Amirah Al Idrus

Foresite Capital banked $969 million in its fifth and biggest raise yet to invest in companies solving some of the biggest inefficiencies in today’s healthcare system. The capital will be split into two funds: About $775 million, or 80%, will go into a core fund, while the remaining $194 million will become what the firm calls an opportunity fund.

Moderna's CMO Zaks quits for 'next leg of his career' after swift move to commercial focus

By Ben Adams

As Moderna ramps up its COVID-19 vaccine efforts and has made one of the speediest moves from a hyped-up preclinical biotech to a commercial entity hoping to help save the world, its chief medical officer, Tal Zaks, M.D., Ph.D., is set to leave for pastures new.

COVID-19 Tracker